Potential Analysis of Human DNA Vaccines Market by Forecast Scenario Analysis (Rapid Growth Scenario, Moderate Growth Scenario, and Low Growth Scenario) - Global Opportunity Analysis and Industry Forecast, 2020-2030

June 2017 | 120 pages | ID: P93F1890FD4EN
Allied Market Research

Abstracts

DNA vaccines are third-generation vaccines and consist of a small circular piece (DNA sequence) of bacterial DNA, which is used for the immunization. DNA vaccine is used for protecting humans against disease by injecting them with genetically engineered DNA to produce an immunological response by activating the host against the gene delivered. DNA vaccines are advantageous over traditional vaccines as the expression of native virus with the antigen is more similar as compared to conventional vaccines, and several antigen or proteins can be delivered in a single dose. In addition, large-scale production can be carried out at a cost lower than conventional method of vaccines. The global potential analysis of DNA vaccines market is expected to account $3,762 million in 2020 and reach $9,337 million by 2030, growing at a CAGR of 9.5% from 2020 to 2030.
The global potential analysis of human DNA vaccine market is segmented based on forecast scenario analysis and region. Based on forecast scenario analysis, it is divided into rapid growth scenario, moderate growth scenario, and low growth scenario. The market analysis based on region includes North America, Europe, Asia-Pacific, and LAMEA.
KEY MARKET BENEFITS

• In-depth study of the global potential market for DNA vaccines is conducted based on the current disease prevalence, target population, and pricing for generating market size and forecast from 2020 to 2030.
• Potential analysis of opportunities is evaluated to understand different aspects of DNA vaccines that are currently under various phases of clinical trials along with the variants that would gain prominence in the future.
• Vaccine pipeline products against DNA, which are under various clinical stages, are covered.
• Key market players are profiled and their strategies are analyzed thoroughly to understand various technologies adopted to manufacture DNA vaccines.

KEY MARKET SEGMENTS

By Forecast Scenario Analysis

• Rapid Growth Scenario
• Moderate Growth Scenario
• Low Growth Scenario

By Region

• North America
• Europe
• Asia-Pacific
• LAMEA

KEY PLAYERS

• Inovio Pharmaceuticals, Inc.
• GeneOne Life Science Inc.
• MedImmune
• Immunomic Therapeutics, Inc.
• Astellas Pharma, Inc.
• Pharos Biologicals
• Sanofi S.A.
• F. Hoffmann-La Roche AG
• CureVac
• Boehringer Ingelheim GmbH

Contents

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
  1.4.1. Secondary research
  1.4.2. Primary research
  1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.3. TOP INVESTMENT POCKETS
3.4. HUMAN DNA VACCINES-KEY FACTS
3.5. REGULATION OF VACCINES BY FDA
3.6. CLINICAL TRIALS
3.7. PRICING FOR TOP GLOBAL VACCINE PRODUCTS
3.8. MARKET OPPORTUNITIES

CHAPTER 4 FORECAST SCENARIO ANALYSIS OF HUMAN DNA VACCINES MARKET

4.1. OVERVIEW
  4.1.1. Market size & forecast
    4.1.1.1. Rapid growth scenario
    4.1.1.2. Moderate growth scenario
    4.1.1.3. Low growth scenario

CHAPTER 5 GLOBAL POTENTIAL ANALYSIS OF HUMAN DNA VACCINES MARKET, BY GEOGRAPHY

5.1. OVERVIEW
5.2. NORTH AMERICA
  5.2.1. Key opportunities
  5.2.2. Market size & forecast
5.3. EUROPE
  5.3.1. Key opportunities
  5.3.2. Market size & forecast
5.4. ASIA-PACIFIC
  5.4.1. Key opportunities
  5.4.2. Market size & forecast
5.5. LAMEA
  5.5.1. Key opportunities
  5.5.2. Market size & forecast

CHAPTER 6 COMPANY PROFILES

6.1. INOVIO PHARMACEUTICALS, INC.
  6.1.1. Overview
  6.1.2. Company snapshot
  6.1.3. Operating business segments
  6.1.4. Business performance
  6.1.5. Product pipeline
  6.1.6. Research funding
  6.1.7. Key strategic developments
6.2. GENEONE LIFE SCIENCE INC.
  6.2.1. Overview
  6.2.2. Company snapshot
  6.2.3. Operating business segments
  6.2.4. Business performance
  6.2.5. Product pipeline
  6.2.6. Research funding
  6.2.7. Key strategic developments
6.3. MEDIMMUNE
  6.3.1. Overview
  6.3.2. Company snapshot
  6.3.3. Operating business segments
  6.3.4. Business performance
  6.3.5. Product pipeline
  6.3.6. Research funding
  6.3.7. Key strategic developments
6.4. IMMUNOMIC THERAPEUTICS, INC.
  6.4.1. Overview
  6.4.2. Company snapshot
  6.4.3. Operating business segments
  6.4.4. Business performance
  6.4.5. Product pipeline
  6.4.6. Research funding
  6.4.7. Strategic moves and developments
6.5. ASTELLAS PHARMA, INC.
  6.5.1. Overview
  6.5.2. Company snapshot
  6.5.3. Operating business segments
  6.5.4. Business performance
  6.5.5. Product pipeline
  6.5.6. Research fuding
  6.5.7. Strategic moves and developments
6.6. PHAROS BIOLOGICALS
  6.6.1. Overview
  6.6.2. Company snapshot
  6.6.3. Operating business segments
  6.6.4. Business performance
  6.6.5. Product pipeline
  6.6.6. Research funding
  6.6.7. Strategic moves and developments
6.7. SANOFI S.A.
  6.7.1. Overview
  6.7.2. Company snapshot
  6.7.3. Operating business segments
  6.7.4. Business performance
  6.7.5. Product pipeline
  6.7.6. Research funding
  6.7.7. Strategic moves and developments
6.8. F. HOFFMANN-LA ROCHE AG
  6.8.1. Overview
  6.8.2. Company snapshot
  6.8.3. Operating business segments
  6.8.4. Business performance
  6.8.5. Product pipeline
  6.8.6. Research funding
  6.8.7. Strategic moves and developments
6.9. CUREVAC
  6.9.1. Overview
  6.9.2. Company snapshot
  6.9.3. Operating business segments
  6.9.4. Business performance
  6.9.5. Product pipeline
  6.9.6. Research fuding
  6.9.7. Strategic moves and developments
6.10. BOEHRINGER INGELHEIM GMBH
  6.10.1. Overview
  6.10.2. Company snapshot
  6.10.3. Operating business segments
  6.10.4. Business performance
  6.10.5. Product pipeline
  6.10.6. Research funding
  6.10.7. Strategic moves and developments

List Of Tables

LIST OF TABLES

TABLE 1. GLOBAL RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 2. GLOBAL MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 3. GLOBAL LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 4. NORTH AMERICA RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 5. NORTH AMERICA MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 6. NORTH AMERICA LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 7. EUROPE RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 8. EUROPE MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 9. EUROPE LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 10. ASIA-PACIFIC RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 11. ASIA-PACIFIC MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 12. ASIA-PACIFIC LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 13. LAMEA RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 14. LAMEA MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 15. LAMEA LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 16. INOVIO PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 17. GENEONE LIFE SCIENCE INC.: COMPANY SNAPSHOT
TABLE 18. MEDIMMUNE: COMPANY SNAPSHOT
TABLE 19. IMMUNOMIC THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 20. ASTELLAS PHARMA, INC.: COMPANY SNAPSHOT
TABLE 21. PHAROS BIOLOGICALS: COMPANY SNAPSHOT
TABLE 22. SANOFI S.A.: COMPANY SNAPSHOT
TABLE 23. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
TABLE 24. CUREVAC: COMPANY SNAPSHOT
TABLE 25. BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT

List Of Figures

LIST OF FIGURES

FIGURE 1. GLOBAL POTENTIAL ANALYSIS OF HUMAN DNA VACCINES MARKET, 2020-2030
FIGURE 2. GLOBAL POTENTIAL ANALYSIS OF HUMAN DNA VACCINES MARKET, BY GEOGRAPHY, 2020-2030
FIGURE 3. MARKET SEGMENTATION
FIGURE 4. TOP INVESTMENT POCKETS
FIGURE 5. GLOBAL POTENTIAL ANALYSIS OF HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 6. GLOBAL RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 7. GLOBAL RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 8. GLOBAL MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 9. GLOBAL MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 10. GLOBAL LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 11. GLOBAL LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 12. NORTH AMERICA RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 13. NORTH AMERICA RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 14. NORTH AMERICA MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 15. NORTH AMERICA MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 16. NORTH AMERICA LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 17. NORTH AMERICA LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 18. EUROPE RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 19. EUROPE RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 20. EUROPE MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 21. EUROPE MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 22. EUROPE LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 23. EUROPE LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 24. ASIA-PACIFIC RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 25. ASIA-PACIFIC RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 26. ASIA-PACIFIC MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 27. ASIA-PACIFIC MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 28. ASIA-PACIFIC LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 29. ASIA-PACIFIC LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 30. LAMEA RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 31. LAMEA RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 32. LAMEA MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 33. LAMEA MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 34. LAMEA LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 35. LAMEA LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020